col blocks we are bridge builder col blocks
COVID Antworten in den wissenschaftlichen Zeitschriften der Welt


34 Ergebisse       Seite 1

 [1] 
Wiley: Pharmacology Research & Perspectives
  Original Artikel Datum Titel Autoren   Alle Autoren
1 [GO] 2025―Mai―02 Supporting Pediatric RSV Clinical Trials Through Close Epidemiological Surveillance During the SARS-CoV-2 Pandemic Rennie Joshi, Georges J. Nahhas, Carmen S. Arriola, Patricia Saddier, Andrea Guerra
2 [GO] 2024―Nov―07 Favipiravir pharmacokinetics in Thai adults with mild COVID-19: A sub-study of interpatient variability and ethnic differences in exposure Ing-orn Prasanchaimontri, Weerawat Manosuthi, Henry Pertinez, Andrew Owen, Suvimol Niyomnaitham, Rujipas Sirijatuphat, et al. (+5)
3 [GO] 2024―Okt―01 Effect of vitamin D supplementation on clinical outcomes in adult patients with COVID-19: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials Zohreh-al-sadat Ghoreshi, Javad Charostad, Nasir Arefinia, Mohsen Nakhaie, Mohammad Rezaei Zadeh Rukerd, Faranak Salajegheh
4 [GO] 2024―Sep―12 An improvement of the safety profile of SARS-CoV-2 vaccines is desirable Josef Finsterer
5 [GO] 2024―Jun―13 Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination László G. Boros, Anthony M. Kyriakopoulos, Carlo Brogna, Marina Piscopo, Peter A. McCullough, Stephanie Seneff
6 [GO] 2024―Jun―12 Incidence and management of the main serious adverse events reported after COVID-19 vaccination Teresa Padilla-Flores, Alicia Sampieri, Luis Vaca
7 [GO] 2024―Apr―04 Ursodeoxycholic acid may protect from severe acute respiratory syndrome coronavirus 2 Omicron variant by reducing angiotensin-converting enzyme 2 Kyungmin Lee, Yujeong Na, Minjin Kim, Dongjin Lee, Jongseo Choi, Gwanyoung Kim, Min-Soo Kim
8 [GO] 2023―Jun―03 Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial Noémie Mercier, Drifa Belhadi, Aline DeChanet, Christelle Delmas, Juliette Saillard, Marina Dumousseaux, et al. (+18)
9 [GO] 2023―Mai―03 The influence of SARS-CoV -2 infection on expression of drug-metabolizing enzymes and transporters in a hACE2 murine model Kiran Deshpande, Keith R. Lange, William B. Stone, Christine Yohn, Naomi Schlesinger, Leonid Kagan, et al. (+3)
10 [GO] 2023―Apr―11 Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID-19 Rodolfo Pedro Rothlin, Facundo Germán Pelorosso, Mariano Duarte, Liliana Nicolosi, Fernandez Criado Ignacio, María Victoria Salgado, Héctor Vetulli
11 [GO] 2022―Dez―20 Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS-CoV -2 neutralizing monoclonal antibody ABBV-47D11 in patients with COVID -19 Mohamad Shebley, Stanley Wang, Izna Ali, Preethi Krishnan, Rakesh Tripathi, Joseph M. Reardon, et al. (+9)
12 [GO] 2022―Sep―01 Toward a big picture of COVID-19 Felix Tretter, Janet J. McIntyre-Mills, Gary R. Smith
13 [GO] 2022―Jul―15 A practical treatment for COVID -19 and the next pandemic Jahar Bhattacharya, Robert Booy, Arturo Casadevall, Charles Dela Cruz, David S. Fedson, Joe G. N. Garcia, et al. (+11)
14 [GO] 2022―Apr―09 Nucleoside analog GS-441524: pharmacokinetics in different species, safety, and potential effectiveness against Covid-19 Henrik Berg Rasmussen, Ragnar Thomsen, Peter Riis Hansen
15 [GO] 2022―Feb―17 Chronic cerebral aspects of long COVID, post-stroke syndromes and similar states share their pathogenesis and perispinal etanercept treatment logic Ian Albert Clark
16 [GO] 2022―Feb―02 Systems analysis shows that thermodynamic physiological and pharmacological fundamentals drive COVID-19 and response to treatment Richard J. Head, Eugenie R. Lumbers, Bevyn Jarrott, Felix Tretter, Gary Smith, Kirsty G. Pringle, et al. (+2)
17 [GO] 2022―Feb―02 The interacting physiology of COVID-19 and the renin-angiotensin-aldosterone system: Key agents for treatment Eugenie R. Lumbers, Richard Head, Gary R. Smith, Sarah J. Delforce, Bevyn Jarrott, Jennifer Martin, Kirsty G. Pringle
18 [GO] 2022―Feb―02 Critical insights to COVID-19 disease and potential treatments using a systems analysis approach that integrates physiology, pharmacology, and clinical pharmacology Jennifer H. Martin, Richard J. Head
19 [GO] 2021―Dez―30 Molnupiravir: A new candidate for COVID-19 treatment Fariba Pourkarim, Samira Pourtaghi-Anvarian, Haleh Rezaee
20 [GO] 2021―Okt―28 Did our pharmacological strategy for COVID-19 fail? Jennifer H. Martin, Michelle Baddeley, Richard Head
21 [GO] 2021―Okt―28 Statin withdrawal and treating COVID-19 patients David S. Fedson
22 [GO] 2021―Okt―10 Bioequivalence and food effect of a fixed-dose combination of macitentan and tadalafil: Adaptive design in the COVID-19 pandemic Dénes Csonka, Vladislav Fishman, Jaya Natarajan, Hans Stieltjes, Danielle Armas, Victor Dishy, Juan Jose Perez Ruixo
23 [GO] 2021―Jun―15 Carrageenan nasal spray may double the rate of recovery from coronavirus and influenza virus infections: Re-analysis of randomized trial data Harri Hemilä, Elizabeth Chalker
24 [GO] 2021―Jun―15 p-cymene impairs SARS-CoV-2 and Influenza A (H1N1) viral replication: In silico predicted interaction with SARS-CoV-2 nucleocapsid protein and H1N1 nucleoprotein Athanasios Panagiotopoulos, Melpomeni Tseliou, Ioannis Karakasiliotis, Danai-Maria Kotzampasi, Vangelis Daskalakis, Nikolaos Kesesidis, et al. (+6)
25 [GO] 2021―Mrz―12 Hemoadsorption eliminates remdesivir from the circulation: Implications for the treatment of COVID-19 Paul Biever, Dawid L. Staudacher, Michaela J. Sommer, Hannah Triebel, Merja A. Neukamm, Christoph Bode, et al. (+2)
26 [GO] 2021―Jan―15 Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview Haleh Rezaee, Fariba Pourkarim, Samira Pourtaghi-Anvarian, Taher Entezari-Maleki, Touraj Asvadi-Kermani, Masoud Nouri-Vaskeh
27 [GO] 2020―Dez―31 Therapeutic approaches against coronaviruses acute respiratory syndrome Camilla Servidio, Francesco Stellacci
28 [GO] 2020―Dez―25 Targeting host cell proteases as a potential treatment strategy to limit the spread of SARS-CoV-2 in the respiratory tract Ismail A. El-Shimy, Mahmoud M. A. Mohamed, Syed Shahzad Hasan, Muhammad A. Hadi
29 [GO] 2020―Okt―30 Nucleotide analogues as inhibitors of SARS-CoV Polymerase Jingyue Ju, Xiaoxu Li, Shiv Kumar, Steffen Jockusch, Minchen Chien, Chuanjuan Tao, et al. (+4)
30 [GO] 2020―Okt―21 A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far? Amanj Kurdi, Nouf Abutheraa, Lina Akil, Brian Godman
31 [GO] 2020―Sep―28 Pharmacological hypothesis: TPC2 antagonist tetrandrine as a potential therapeutic agent for COVID-19 Paula M. Heister, Robin N. Poston
32 [GO] 2020―Jul―27 Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients Bruce M. Hendry, Nina Stafford, Ahran D. Arnold, Arvind Sangwaiya, Vijay Manglam, Stuart D. Rosen, Jayantha Arnold
33 [GO] 2020―Jul―13 The renin-angiotensin-aldosterone system: Role in pathogenesis and potential therapeutic target in COVID-19 Cássia L. Braga, Rodrigo P. Silva-Aguiar, Denise Battaglini, Diogo B. Peruchetti, Chiara Robba, Paolo Pelosi, et al. (+3)
34 [GO] 2020―Jun―24 Buying time: Drug repurposing to treat the host in COVID-19H Jennifer H. Martin, Julian Clark, Richard Head
 [1] 

34 Ergebisse       Seite 1


[de][en]

Letzte Änderung 2023―Okt―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.004 sec